Form 8-K - Current report:
SEC Accession No. 0000899923-26-000059
Filing Date
2026-06-04
Accepted
2026-06-04 16:08:53
Documents
14
Period of Report
2026-06-04
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mygn-20260604.htm   iXBRL 8-K 62761
2 EX-10.1 ex1012012esppasamendedjune.htm EX-10.1 56369
3 EX-10.2 ex102myriad-2026employeedi.htm EX-10.2 151453
  Complete submission text file 0000899923-26-000059.txt   456445

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mygn-20260604.xsd EX-101.SCH 2021
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mygn-20260604_def.xml EX-101.DEF 14426
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mygn-20260604_lab.xml EX-101.LAB 25279
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mygn-20260604_pre.xml EX-101.PRE 15012
17 EXTRACTED XBRL INSTANCE DOCUMENT mygn-20260604_htm.xml XML 2707
Mailing Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116
Business Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116 801-584-3600
MYRIAD GENETICS INC (Filer) CIK: 0000899923 (see all company filings)

EIN.: 870494517 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-26642 | Film No.: 261064987
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)